查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017737

微量採樣和微創血液採集市場規模、佔有率和趨勢分析報告：按產品、應用、最終用途、地區和細分市場分類（2026-2033 年）

Microsampling & Minimally Invasive Blood Collection Market Size, Share & Trends Analysis Report By Product, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

微量採樣和微創血液採集市場概述

全球微量採樣和微創血液採集市場預計在 2025 年達到 21.6 億美元，預計到 2033 年將達到 40.1 億美元，2026 年至 2033 年的複合年成長率為 8.15%。

這一成長是由慢性病在全球範圍內日益加重的負擔、對以患者為中心的診斷護理日益成長的需求以及分散式臨床試驗 (DCT) 中遠程微採樣技術的不斷普及所推動的。

血液分析在診斷中仍然發揮著至關重要的作用，從而支撐著產業的擴張。傳統的診斷方法主要依賴在中心實驗室採集動脈血，而分子診斷技術的進步使得只需少量檢體即可獲得準確的結果。這種轉變正在加速向分散式醫療模式的轉型，微量採樣提高了患者就診的便利性，增強了遠端偵測能力，最終促進了更廣泛的應用和市場的永續成長。

全球慢性病負擔持續加重，推動了微量採樣和非侵入性採血技術的日益普及。根據世界衛生組織（世衛組織）統計，2021年約有4,300萬人死於慢性病，約佔全球整體非疫情死亡總數的75%，其中1,800萬人死於70歲之前的過早死亡。日益成長的疾病負擔促使人們對持續、經濟高效且擴充性的診斷監測解決方案的需求不斷成長。有效管理慢性病並實現早期療育需要頻繁且長期的血液檢測。然而，傳統的靜脈採血方法仍耗費大量資源，且具有間歇性，並常常限制了檢測的可及性和患者的依從性。

以患者為中心的診斷護理日益成長的需求是微量採樣和微創血液採樣市場成長的主要驅動力。醫療保健系統越來越重視能夠提高患者舒適度、便利性和可近性的解決方案，尤其對於需要頻繁監測的患者，例如慢性疾病患者、兒童和老年人。微量採樣技術可透過指尖採血和微針系統等先進設備採集少量毛細血管血，支援居家和分散式檢查，從而減少對傳統臨床環境的依賴。這一趨勢與遠端醫療和遠距照護模式的快速發展相吻合，在這些模式中，自採試劑盒和郵購診斷服務正變得越來越標準化。此外，容積吸收微量採樣 (VAMS) 和改進的乾血斑 (DBS)調查方法等技術進步正在解決諸如血球比容變異性等傳統難題，並確保結果的準確性和可重複性。因此，微量取樣在治療藥物監測和分散式臨床試驗 (DCT) 等領域越來越受到關注，其優勢包括快速提供檢測結果、降低物流成本和提高患者依從性。

持續的技術進步在加速分散式臨床試驗 (DCT) 中微量採樣技術的應用方面發揮著至關重要的作用。諸如體積吸收微量採樣 (VAMS)、先進的乾血斑 (DBS) 技術和新一代微針設備等創新技術顯著提高了檢體的準確性、一致性和易用性。這些進步解決了檢體量變異性和血球比容值影響等傳統難題，即使是遠端採集的檢體也能獲得實驗室層級的數據品質。從臨床試驗的角度來看，遠端微量採樣減少了對實體實驗室的依賴，使參與者能夠在家中自行採集檢體並將其發送至中心實驗室。這種方法有助於招募參與者，尤其是在地理位置分散或服務不足的地區，同時透過最大限度地減少出行和檢測流程的負擔來提高參與率。此外，諸如具有遠端離心功能的血清微量採樣設備和運輸條件控制技術等進步確保了分析物的穩定性，從而保證了可靠的臨床和蛋白質組學分析。因此，微抽樣正在成為擴充性的、以患者為中心的分散式臨床試驗 (DCT) 模型的關鍵促進因素，有助於縮短試驗時間、降低營運成本並提高患者多樣性。

在臨床前研究中採用微量取樣技術具有顯著的倫理和操作優勢，尤其是在藥物動力學 (TK) 研究中。傳統的採血方法通常需要較大的檢體量和重複採集，這可能會加劇毒性反應並增加實驗動物的生理壓力。相較之下，微量取樣技術可以透過微創方式採集少量血液，從而減輕動物的痛苦並改善其整體福祉。諸如聯合取樣等技術可以進一步減少採血的頻率和總量，符合動物研究中減少和最佳化的原則。此外，微量取樣可以加快檢體採集速度，減少動物和技術人員的操作時間，進而提高工作流程效率。使用更細的針頭和創傷更小的技術可以最大限度地減少組織損傷和不適，有助於符合倫理規範和獲得監管部門的核准。例如，在使用囓齒動物進行的藥物動力學研究中，微量取樣可以在保持高品質數據輸出的同時減少動物的使用數量，因為它允許從同一隻動物進行連續取樣，而無需大規模動物數量。

微量採樣和非侵入性採血技術正在透過提高數據品質和操作效率，變革臨床診斷和研究。例如，乾基質微量採樣（包括乾血斑 (DBS)）等技術可最大限度地減少血液與空氣的接觸，並保存藥物、代謝物和 RNA 等敏感分析物。 3D 血球和預處理 DBS 卡等先進技術進一步提高了麩胺基硫和可卡因等不穩定化合物的穩定性，而體積吸收微量採樣 (VAMS) 則可實現精確的定量採血，並有效消除與血細胞比容值相關的變異性。此外，HemaPEN 和 HemaXis 等設備可提高檢體均一性，緩解「咖啡環效應」等問題，並確保結果的可靠性和可重複性。除了分析優勢外，微量採樣還顯著降低了物流複雜性，因為乾燥檢體可以在室溫下運輸，無需高成本的低溫運輸基礎設施。此外，遠端和自採集功能支援居家和分散式檢體採集，從而減少了對訓練有素的血液科醫生和專業臨床機構的依賴。由於僅需少量檢體，儲存空間需求也降至最低，最終實現了從常規診斷到分散式臨床試驗的高度擴充性和成本效益的工作流程。

儘管市場正經歷強勁成長，但日益嚴格的監管審查顯然要求微量採樣設備必須展現出與傳統檢測方法相當的性能。同時，策略整合也在加劇，大型企業紛紛收購專業創新企業，以增強自身能力並擴大市場佔有率。該領域的成功取決於能否持續證明其可靠性符合既定標準，並滿足複雜的監管要求。此外，先進且易於使用的微量採樣設備的高成本可能成為推廣應用的障礙，尤其是在價格敏感的市場和保險報銷支援有限的地區。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 微量採樣和微創血液採集市場：變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 微量採樣和微創血液採集市場分析工具

第4章 微量採樣和微創血液採集市場：產品特定估算和趨勢分析

  • 微量採樣和微創血液採集市場：基於產品的波動分析
  • 微量採樣與微創血液採集市場：產品展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 微量取樣設備
    • 體積吸收微量採樣（VAMS）裝置
    • 按鈕式採血裝置
    • 微流體血液採集裝置
  • 微血管採血裝置
    • 《採血針》
    • 穿刺裝置
    • 毛細管/微量採血管
    • 微型血液採集容器
  • 乾血斑 (DBS) 採集裝置
    • 乾血斑（DBS）卡
    • 乾血斑 (DBS) 採集試劑盒
  • 家用採血裝置
    • 用於自行採集血液的採血裝置
    • 遠端採血套件

第5章 微量採樣和微創血液採集市場：按應用分類的估算和趨勢分析

  • 微量採樣和微創採血市場：基於應用的波動分析
  • 微量採樣和微創血液採集市場：基於應用的展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 疾病診斷
  • 治療藥物監測（TDM）
  • 臨床試驗/分散式臨床試驗
  • 新生兒和基因篩檢
  • 健康檢查及預防性體檢

第6章：微量採樣和微創血液採集市場：按最終用途分類的估算和趨勢分析

  • 微量採樣和微創血液採集市場：按最終用途分類的波動分析
  • 微量採樣和微創血液採集市場：按最終用途分類的展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 醫院和診所
  • 診斷檢查室
  • 製藥和生物技術公司/合約研究組織
  • 研究和學術機構
  • 居家醫療/自我檢查

第7章 微量採樣和微創血液採集市場：區域估算和趨勢分析

  • 區域儀錶板
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 其他亞太國家
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特
    • 其他中東和非洲國家

第8章 競爭情勢

  • 參與企業的分類
  • 主要市場參與企業的最新趨勢及影響分析
  • 企業市場占有率分析，2025 年
  • 主要企業簡介
    • BD
    • Abbott
    • F. Hoffmann-La Roche Ltd
    • PerkinElmer
    • Terumo Corp
    • Neoteryx
    • Tasso Inc.
    • Sarstedt AG & Co. KG
    • Seventh Sense Biosystems.
    • Capitainer AB
Product Code: GVR-4-68040-882-8

Microsampling & Minimally Invasive Blood Collection Market Summary

The global microsampling & minimally invasive blood collection market size was estimated at USD 2.16 billion in 2025 and is projected to reach USD 4.01 billion by 2033, growing at a CAGR of 8.15% from 2026 to 2033. The growth is driven by the increasing global burden of chronic conditions, rising demand for patient-centric diagnostic care, and ongoing technological advancements, supported by the expanding adoption of remote microsampling into decentralized clinical trials (DCTs).

Blood-based analysis continues to play a critical role in diagnostics, thereby underpinning the expansion of the industry. While traditional diagnostic approaches have largely relied on arterial blood collection in centralized laboratory settings, advancements in molecular diagnostics are now enabling accurate results from significantly smaller sample volumes. This transition is facilitating a shift toward decentralized healthcare models, with microsampling enhancing patient access, convenience, and remote testing capabilities, ultimately contributing to broader adoption and sustained market growth.

The global burden of chronic diseases continues to rise, driving increased adoption of microsampling and non-invasive blood collection technologies. According to the World Health Organization (WHO), chronic diseases accounted for approximately 43 million deaths in 2021, representing nearly 75% of all non-pandemic-related deaths worldwide, including 18 million premature deaths occurring before the age of 70. This escalating disease burden is translating into sustained demand for continuous, cost-effective, and scalable diagnostic monitoring solutions. Chronic conditions necessitate frequent and longitudinal blood-based testing to enable effective disease management and early intervention. However, traditional venous sampling approaches remain resource-intensive, episodic in nature, and often pose limitations in accessibility and patient compliance.

The increasing demand for patient-centric diagnostic care is a key driver of growth in the microsampling and minimally invasive blood collection market. Healthcare systems are progressively prioritizing solutions that enhance patient comfort, convenience, and accessibility, particularly for individuals requiring frequent monitoring, such as patients with chronic diseases, as well as pediatric and geriatric populations. Microsampling technologies, which enable low-volume capillary blood collection through finger-stick methods or advanced devices such as microneedle-based systems, support at-home and decentralized testing, thereby reducing reliance on conventional clinical settings. This trend aligns with the rapid expansion of telehealth and remote care models, where self-collection kits and mail-in diagnostic services are becoming increasingly standardized. In addition, advancements such as volumetric absorptive microsampling (VAMS) and improved dried blood spot (DBS) methodologies address historical limitations like hematocrit variability, ensuring accurate and reproducible results. Consequently, microsampling is gaining traction in applications such as therapeutic drug monitoring and decentralized clinical trials, driven by benefits including faster turnaround times, lower logistical costs, and improved patient adherence.

Ongoing technological advancements are playing a critical role in accelerating the adoption of microsampling within decentralized clinical trials (DCTs). Innovations such as volumetric absorptive microsampling (VAMS), advanced dried blood spot (DBS) techniques, and next-generation microneedle-based devices have significantly enhanced sample accuracy, consistency, and ease of use. These developments address historical limitations, including variability in sample volume and hematocrit effects, thereby enabling laboratory-grade data quality from remotely collected samples. From a clinical trial perspective, the integration of remote microsampling allows participants to self-collect samples at home and ship them to centralized laboratories, reducing dependence on physical trial sites. This approach supports improved patient recruitment, particularly across geographically dispersed and underserved populations, while also enhancing retention by minimizing travel and procedural burden. Furthermore, advancements such as serum microsampling devices with remote centrifugation capabilities and controlled shipping conditions help maintain analyte stability and ensure reliable clinical and proteomic analyses. Consequently, microsampling is emerging as a key enabler of scalable and patient-centric DCT models, supporting faster trial timelines, reduced operational costs, and improved diversity in patient representation.

The adoption of microsampling in preclinical research offers significant ethical and operational advantages, particularly in toxicokinetic (TK) studies. Conventional blood collection methods often require larger sample volumes and repeated sampling, which can exacerbate toxicity responses and increase physiological stress in study animals. In contrast, microsampling techniques enable the collection of smaller blood volumes through minimally invasive approaches, thereby reducing animal distress and improving overall welfare. Approaches such as composite sampling further minimize the frequency and total volume of blood draws, aligning with the principles of reduction and refinement in animal research. In addition, microsampling enhances workflow efficiency by enabling faster sample collection and reducing handling time for both animals and technical personnel. The use of smaller gauge needles and less invasive techniques minimizes tissue damage and discomfort, supporting ethical compliance and regulatory acceptance. For instance, in rodent TK studies, microsampling facilitates serial sampling from the same animal rather than requiring larger cohorts, thereby reducing animal usage while maintaining high-quality data outputs.

Microsampling and non-invasive blood collection technologies are transforming clinical diagnostics and research by enhancing both data quality and operational efficiency. Techniques such as dried matrix microsampling, including dried blood spots (DBS), minimize blood exposure to air, thereby preserving sensitive analytes such as drugs, metabolites, and RNA. Advanced innovations, including 3D blood spheroids and pre-treated DBS cards, further improve the stability of labile compounds such as glutathione and cocaine, while volumetric absorptive microsampling (VAMS) enables precise fixed-volume collection, effectively addressing hematocrit-related variability. Additionally, devices such as HemaPEN and HemaXis enhance sample homogeneity and mitigate issues like the "coffee ring effect," ensuring reliable and reproducible results. Beyond analytical advantages, microsampling significantly reduces logistical complexity, as dried samples can be transported at ambient temperatures, eliminating the need for costly cold-chain infrastructure. Furthermore, remote and self-sampling capabilities support at-home and decentralized collection, reducing reliance on trained phlebotomists and specialized clinical facilities. Low-volume sample requirements also minimize storage needs, enabling scalable and cost-efficient workflows across routine diagnostics and decentralized clinical trials.

While the market is experiencing strong growth, it is also subject to increasing regulatory scrutiny and a clear requirement to demonstrate performance comparable to conventional testing methods. At the same time, strategic consolidation is intensifying, with larger players acquiring specialized innovators to strengthen their capabilities and expand market presence. Success in this space will depend on the ability to navigate complex regulatory requirements while consistently proving reliability against established standards. In addition, the high cost of advanced, user-friendly microsampling devices may act as a barrier to adoption, particularly in price-sensitive markets and regions with limited reimbursement support.

Global Microsampling & Minimally Invasive Blood Collection Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global microsampling & minimally invasive blood collection market report on the basis of product, application, end-use, and region:

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Microsampling Devices
    • Volumetric Absorptive Microsampling (VAMS) Devices
    • Push-Button Blood Collection Devices
    • Microfluidic Blood Sampling Devices
  • Capillary Blood Collection Devices
    • Lancets
    • Lancing Devices
    • Capillary Tubes / Microcollection Tubes
    • Microcollection Containers
  • Dried Blood Spot (DBS) Collection Devices
    • Dried Blood Spot (DBS) Cards
    • Dried Blood Spot (DBS) Collection Kits
  • At-Home Blood Collection Devices
    • Self-Collection Blood Sampling Devices
    • Remote Blood Collection Kits
  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Disease Diagnostics
  • Therapeutic Drug Monitoring (TDM)
  • Clinical Trials / Decentralized Clinical Trials
  • Neonatal & Genetic Screening
  • Health Screening & Preventive Testing
  • End-use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies / CROs
  • Research & Academic Institutes
  • Homecare / Self-Testing
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End-use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Microsampling & Minimally Invasive Blood Collection Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising global burden of chronic conditions
      • 3.2.1.2. Patient centric care & comfort
      • 3.2.1.3. Integration of remote microsampling into decentralized clinical trials
      • 3.2.1.4. Ethical Advantages in Preclinical Research
      • 3.2.1.5. Improved Data Quality & Stability
      • 3.2.1.6. Lower logistical Overhead
      • 3.2.1.7. Technological Advancements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory and compliance hurdles
      • 3.2.2.2. High cost of advanced devices
  • 3.3. Microsampling & Minimally Invasive Blood Collection Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Microsampling & Minimally Invasive Blood Collection Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Microsampling & Minimally Invasive Blood Collection Market: Product Movement Analysis
  • 4.3. Microsampling & Minimally Invasive Blood Collection Market by Product Outlook (USD Billion)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Microsampling Devices
    • 4.5.1. Microsampling Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Volumetric Absorptive Microsampling (VAMS) Devices
      • 4.5.2.1. Volumetric Absorptive Microsampling (VAMS) Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Push-Button Blood Collection Devices
      • 4.5.3.1. Push-Button Blood Collection Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Microfluidic Blood Sampling Devices
      • 4.5.4.1. Microfluidic Blood Sampling Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Capillary Blood Collection Devices
    • 4.6.1. Capillary Blood Collection Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Lancets
      • 4.6.2.1. Lancets Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Lancing Devices
      • 4.6.3.1. Lancing Devices Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Capillary Tubes / Microcollection Tubes
      • 4.6.4.1. Capillary Tubes / Microcollection Tubes Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.5. Microcollection Containers
      • 4.6.5.1. Microcollection Containers Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Dried Blood Spot (DBS) Collection Devices
    • 4.7.1. Dried Blood Spot (DBS) Collection Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.7.2. Dried Blood Spot (DBS) Cards
      • 4.7.2.1. Dried Blood Spot (DBS) Cards Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.7.3. Dried Blood Spot (DBS) Collection Kits
      • 4.7.3.1. Dried Blood Spot (DBS) Collection Kits Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. At-Home Blood Collection Devices
    • 4.8.1. At-Home Blood Collection Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.8.2. Self-Collection Blood Sampling Devices
      • 4.8.2.1. Self-Collection Blood Sampling Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.8.3. Remote Blood Collection Kits
      • 4.8.3.1. Remote Blood Collection Kits Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Microsampling & Minimally Invasive Blood Collection Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Microsampling & Minimally Invasive Blood Collection Market: Application Movement Analysis
  • 5.3. Microsampling & Minimally Invasive Blood Collection Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Disease Diagnostics
    • 5.5.1. Disease Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Therapeutic Drug Monitoring (TDM)
    • 5.6.1. Therapeutic Drug Monitoring (TDM) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Clinical Trials / Decentralized Clinical Trials
    • 5.7.1. Clinical Trials / Decentralized Clinical Trials Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Neonatal & Genetic Screening
    • 5.8.1. Blood Based Tests Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Health Screening & Preventive Testing
    • 5.9.1. Health Screening & Preventive Testing Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Microsampling & Minimally Invasive Blood Collection Market: End-use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Microsampling & Minimally Invasive Blood Collection Market: End-use Movement Analysis
  • 6.3. Microsampling & Minimally Invasive Blood Collection Market by End-use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Hospitals & Clinics
    • 6.5.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Pharmaceutical & Biotechnology Companies / CROs
    • 6.7.1. Pharmaceutical & Biotechnology Companies / CROs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Research & Academic Institutes
    • 6.8.1. Research & Academic Institutes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Homecare / Self-Testing
    • 6.9.1. Homecare / Self-Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Microsampling & Minimally Invasive Blood Collection Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.9. Rest of Europe
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Regulatory framework/ reimbursement structure
      • 7.4.9.3. Competitive scenario
      • 7.4.9.4. Rest of Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.7. Rest of Asia Pacific
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework/ reimbursement structure
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Rest of Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. Rest of Latin America
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Rest of Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. Rest of MEA
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Rest of MEA market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2025
  • 8.4. Key Company Profiles
    • 8.4.1. BD
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Abbott
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. F. Hoffmann-La Roche Ltd
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. PerkinElmer
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Terumo Corp
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Neoteryx
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Tasso Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Sarstedt AG & Co. KG
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Seventh Sense Biosystems.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Capitainer AB
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 4. Global Microsampling & Minimally Invasive Blood Collection market, by application, 2021 - 2033 (USD Million)
  • Table 5. Global Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 6. Global Microsampling & Minimally Invasive Blood Collection market, by region, 2021 - 2033 (USD Million)
  • Table 7. North America Microsampling & Minimally Invasive Blood Collection market, by country, 2021 - 2033 (USD Million)
  • Table 8. North America Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 9. North America Microsampling & Minimally Invasive Blood Collection market, by application, 2021 - 2033 (USD Million)
  • Table 10. North America Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 11. U.S. Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 12. U.S. Microsampling & Minimally Invasive Blood Collection market, by application, 2021 - 2033 (USD Million)
  • Table 13. U.S. Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 14. Canada Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 15. Canada Microsampling & Minimally Invasive Blood Collection market, by application, 2021 - 2033 (USD Million)
  • Table 16. Canada Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 17. Mexico Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 18. Mexico Microsampling & Minimally Invasive Blood Collection market, by application, 2021 - 2033 (USD Million)
  • Table 19. Mexico Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 20. Europe Microsampling & Minimally Invasive Blood Collection market, by country, 2021 - 2033 (USD Million)
  • Table 21. Europe Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 22. Europe Microsampling & Minimally Invasive Blood Collection market, by application, 2021 - 2033 (USD Million)
  • Table 23. Europe Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 24. UK Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 25. UK Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 26. UK Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 27. Germany Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 28. Germany Microsampling & Minimally Invasive Blood Collection market, by Application 2021 - 2033 (USD Million)
  • Table 29. Germany Microsampling & Minimally Invasive Blood Collection market, by end use 2021 - 2033 (USD Million)
  • Table 30. France Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 31. France Microsampling & Minimally Invasive Blood Collection market, by Application 2021 - 2033 (USD Million)
  • Table 32. France Microsampling & Minimally Invasive Blood Collection market, by end use 2021 - 2033 (USD Million)
  • Table 33. Italy Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 34. Italy Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 35. Italy Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 36. Spain Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 37. Spain Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 38. Spain Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 39. Denmark Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 40. Denmark Microsampling & Minimally Invasive Blood Collection market, by Application 2021 - 2033 (USD Million)
  • Table 41. Denmark Microsampling & Minimally Invasive Blood Collection market, by end use 2021 - 2033 (USD Million)
  • Table 42. Sweden Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 43. Sweden Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 44. Sweden Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 45. Norway Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 46. Norway Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 47. Norway Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 48. Rest of Europe Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 49. Rest of Europe Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 50. Rest of Europe Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 51. Asia Pacific Microsampling & Minimally Invasive Blood Collection market, by country, 2021 - 2033 (USD Million)
  • Table 52. Asia Pacific Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 53. Asia Pacific Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 54. Asia Pacific Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 55. Japan Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 56. Japan Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 57. Japan Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 58. China Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 59. China Microsampling & Minimally Invasive Blood Collection market, by Application 2021 - 2033 (USD Million)
  • Table 60. China Microsampling & Minimally Invasive Blood Collection market, by end use 2021 - 2033 (USD Million)
  • Table 61. India Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 62. India Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 63. India Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 64. Australia Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 65. Australia Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 66. Australia Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 67. South Korea Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 68. South Korea Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 69. South Korea Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 70. Thailand Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 71. Thailand Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 72. Thailand Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 73. Rest of Asia Pacific Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 74. Rest of Asia Pacific Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 75. Rest of Asia Pacific Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 76. Latin America Microsampling & Minimally Invasive Blood Collection market, by country, 2021 - 2033 (USD Million)
  • Table 77. Latin America Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 78. Latin America Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 79. Latin America Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 80. Brazil Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 81. Brazil Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 82. Brazil Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 83. Argentina Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 84. Argentina Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 85. Argentina Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 86. Rest of Latin America Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 87. Rest of Latin America Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 88. Rest of Latin America Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 89. Middle East & Africa Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 90. Middle East & Africa Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 91. Middle East & Africa Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 92. South Africa Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 93. South Africa Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 94. South Africa Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 95. Saudi Arabia Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 96. Saudi Arabia Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 97. Saudi Arabia Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million
  • Table 98. UAE Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 99. UAE Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 100. UAE Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 101. Kuwait Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 102. Kuwait Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 103. Kuwait Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)
  • Table 104. Rest of MEA Microsampling & Minimally Invasive Blood Collection market, by product, 2021 - 2033 (USD Million)
  • Table 105. Rest of MEA Microsampling & Minimally Invasive Blood Collection market, by Application, 2021 - 2033 (USD Million)
  • Table 106. Rest of MEA Microsampling & Minimally Invasive Blood Collection market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Microsampling & minimally invasive blood collection market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Microsampling & minimally invasive blood collection market, product outlook key takeaways 2025 & 2033 (USD Million)
  • Fig. 12 Microsampling & minimally invasive blood collection market, product analysis 2025 & 2033 (USD Million)
  • Fig. 13 Microsampling devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 Volumetric absorptive Microsampling (VAMS) Devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 15 Push-Button blood collection Devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 Microfluidic blood sampling Devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Instruments & systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Lancets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Lancing devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Capillary tubes / microcollection tubes market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Microcollection containers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Dried blood spot (DBS) collection devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Dried blood spot (DBS) cards market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Dried blood spot (DBS) collection kits market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 At-home blood collection devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Self-collection blood sampling devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Remote blood collection kits market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Microsampling & minimally invasive blood collection market, application outlook key takeaways 2025 & 2033 (USD Million)
  • Fig. 29 Microsampling & minimally invasive blood collection market, application analysis 2025 & 2033 (USD Million)
  • Fig. 30 Disease diagnostics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Therapeutic drug monitoring (TDM) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Clinical trials / decentralized clinical trials market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Neonatal & genetic screening market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Health screening & preventive testing market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Microsampling & minimally invasive blood collection market, end use outlook key takeaways 2025 & 2033 (USD Million)
  • Fig. 36 Microsampling & minimally invasive blood collection market, end use analysis 2025 & 2033 (USD Million)
  • Fig. 37 Hospitals & clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Diagnostic laboratories market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Pharmaceutical & biotechnology companies / CROs market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Research & academic institutes market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Homecare / self-testing revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 North America microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 US microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Canada microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Mexico microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 UK microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Germany microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 France microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Spain microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Italy microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Sweden microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Norway microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Rest of Europe microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Asia Pacific microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 China microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Japan microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 India microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 South Korea microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Australia microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Thailand microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Rest of Asia Pacific microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Latin America microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Brazil microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Rest of Latin America microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Middle East and Africa microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 UAE microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Kuwait microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Rest of MEA microsampling & minimally invasive blood collection market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 List of key emerging company's